Dermatology Daily Report:01/18/2024

A Phase 2, randomised, double-blinded, placebo-controlled, 52-week study, investigated the effect of secukinumab in patients with moderate to severe psoriasis (1). The study enrolled 24 patients and found that after 52 weeks, 14 patients were considered clinical responders (≥75% improvement in Psoriasis Area and Severity Index [PASI]; PASI75), 4 were non-responders (<PASI75), and 6 were lost to follow-up. Both histological and transcriptomic profiles of PASI75 responders improved from Week 12-52. The study highlighted the long-term effects of secukinumab on the molecular resolution of psoriatic inflammation.

Reference

Tomalin LE, Kolbinger F, Suprun M, Wharton KA Jr, Hartmann N, Peters T, Glueck A, Milutinovic M, Krueger JG, Suárez-Fariñas M. Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab. Clin Exp Dermatol. 2024 Jan 18:llae006. doi: 10.1093/ced/llae006. Epub ahead of print. PMID: 38240024.